{"organizations": ["PharmaCyte Biotech Inc."], "uuid": "79521a9a6343ca36662877412cf254e04fd5d52a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://feeds.bio-medicine.org/latest-biology-technology", "section_title": "Latest Biology Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/biology-technology-1/Investor-Update-3A-PharmaCyte-Biotech-Due-Diligence-Report---Small-Cap-Street-34335-1/", "country": "US", "title": "Investor Update: PharmaCyte Biotech Due Diligence Report - Small Cap Street", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "Investor Update: PharmaCyte Biotech Due Diligence Report - Small Cap Street", "spam_score": 0.0, "site_type": "news", "published": "2015-10-13T20:12:00.000+03:00", "replies_count": 0, "uuid": "79521a9a6343ca36662877412cf254e04fd5d52a"}, "author": "", "url": "http://www.bio-medicine.org/biology-technology-1/Investor-Update-3A-PharmaCyte-Biotech-Due-Diligence-Report---Small-Cap-Street-34335-1/", "ord_in_thread": 0, "title": "Investor Update: PharmaCyte Biotech Due Diligence Report - Small Cap Street", "locations": ["NEW YORK"], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "RSS Navigation Links HOME >> BIOLOGY >> TECHNOLOGY Investor Update: PharmaCyte Biotech Due Diligence Report - Small Cap Street ... NEW YORK Oct. 13 2015 /- Phar...Our due diligence will show investors in PharmaCyte Biotech Inc. info... http://bit.ly/-PMCB...Copy and paste to browser may be required. !-- Paragraph before: ... http://feeds.bio-medicine.org/latest-biology-technology Date:10/13/2015 \nNEW YORK , Oct. 13, 2015 /PRNewswire/ -- PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.1035, off 3.09% in yesterday's session. Trading volume was at near average with 1,308,352 shares being traded. PMCB shares have been soft in the second half of this year hitting a low of $.072 in September, then bouncing back to current levels. \nOur due diligence will show investors in PharmaCyte Biotech, Inc. information they need to make investment choices. Get our report by using the link below at no cost. \nCopy and paste to browser may be required. \nAbout PharmaCyte Biotech \nPharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-BoxÂ®\". This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced pancreatic cancer and its symptoms, and diabetes are being developed. \nAbout Small Cap Street \nWe make the connection between sophisticated investors and high quality public companies. An issuer of reports written by financial analysts who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. \nSafe Harbor Statement \nThis press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements \nCompliance Procedure \nContent is researched, written and reviewed on a best-effort basis by a 3rd party research provider. However, we are only human and may make mistakes. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.", "external_links": [], "published": "2015-10-13T20:12:00.000+03:00", "crawled": "2015-10-14T16:18:24.530+03:00", "highlightTitle": ""}